LINNOVATE: A Phase 1/2 Study of Safety/Efficacy Using LURBINECTEDIN, Combined With IPILIMUMAB, and NIVOLUMAB for Advanced Soft Tissue Sarcomas
Latest Information Update: 13 Jan 2025
At a glance
- Drugs Ipilimumab (Primary) ; Lurbinectedin (Primary) ; Nivolumab (Primary)
- Indications Endometrial cancer; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions
- Acronyms LINNOVATE
Most Recent Events
- 09 Sep 2024 According to Jazz Pharmaceuticals media release, the company will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona, Spain.
- 10 Apr 2024 Trial design presented at the 115th Annual Meeting of the American Association for Cancer Research.
- 07 Jun 2023 Status changed from not yet recruiting to recruiting.